Approval · Notice of Compliance 14176 · 2013
NIMENRIX: Notice of Compliance 14176
Issued March 5, 2013
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 14176
- Date
- March 5, 2013
- Company
- Glaxosmithkline IncMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- New Drug Submission (NDS)
- Submission class
- New Active Substance (NAS)
- Therapeutic class
- Active immunizing agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| NIMENRIX | 02402904 | Marketed |
Medicinal ingredients
- MENINGOCOCCAL POLYSACCHARIDE ANTIGEN GROUP A 5 MCG per 0.5ML
- MENINGOCOCCAL POLYSACCHARIDE ANTIGEN GROUP C 5 MCG per 0.5ML
- MENINGOCOCCAL POLYSACCHARIDE ANTIGEN GROUP Y 5 MCG per 0.5ML
- TETANUS TOXOID 44 MCG per 0.5ML
- MENINGOCOCCAL POLYSACCHARIDE ANTIGEN GROUP W-135 5 MCG per 0.5ML